Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoylglycerol and arachidonoyl-ethanolamide, and their metabolites

Journal of Leukocyte Biology

Volumn 97, Issue 6, 2015, Pages 1049-1070

  Turcotte, Caroline ^a   Chouinard, François ^a   Lefebvre, Julie S ^a   Flamand, Nicolas ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Anandamide; Eicosanoid; Leukocyte; Leukotriene; MAG lipase; Prostaglandin

Indexed keywords

ANANDAMIDE; ANTIINFLAMMATORY AGENT; CANNABINOID RECEPTOR; ENDOCANNABINOID; ENDOCANNABINOIDS 2 ARACHIDONOYLGLYCEROL; GLYCEROL DERIVATIVE; LIPIDOME; UNCLASSIFIED DRUG; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; PHOSPHATIDIC ACID;

ANTIINFLAMMATORY ACTIVITY; CYCLOOXYGENATION; DRUG EFFECT; DRUG METABOLISM; DRUG SYNTHESIS; EPOXYGENATION; HUMAN; HYDROLYSIS; IMMUNOCOMPETENT CELL; INFLAMMATION; LIPID METABOLISM; LIPOXYGENATION; OXYGENATION; PRIORITY JOURNAL; REVIEW; ANIMAL; DEGENERATIVE DISEASE; DENDRITIC CELL; IMMUNOLOGY; LIVER DISEASE; LYMPHOCYTE; METABOLIC SYNDROME X; METABOLISM; OBESITY; PAIN; PATHOLOGY;

ANIMALS; ARACHIDONIC ACIDS; DENDRITIC CELLS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; INFLAMMATION; LIPID METABOLISM; LIVER DISEASES; LYMPHOCYTES; METABOLIC SYNDROME X; NEURODEGENERATIVE DISEASES; OBESITY; PAIN; PHOSPHATIDIC ACIDS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID;

EID: 84930257679     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3RU0115-021R     Document Type: Review

References (298)

1. Baudelaire, C. (1860) Les Paradis Artificiels: du Vin et du Haschish. Paris: Poulet Malassis.
2. Touw, M. (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. J. Psychoactive Drugs 13, 23–34.
3. Di Marzo, V., Matias, I. (2005) Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8, 585–589.
4. Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Walker, J. M., Holmes, P. V., Crystal, J. D., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Piomelli, D. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108–1112.
5. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300–302.
6. Gaoni, Y., Mechoulam, R. (1964) Isolation, structure elucidation and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647.
7. Melvin, L. S., Johnson, M. R., Harbert, C. A., Milne, G. M., Weissman, A. (1984) A cannabinoid derived prototypical analgesic. J. Med. Chem. 27, 67–71.
8. Melvin, L. S., Johnson, M. R. (1987) Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res. Monogr. 79, 31–47.
9. Johnson, M. R., Melvin, L. S., Milne, G. M. (1982) Prototype cannabinoid analgetics, prostaglandins and opiates—a search for points of mechanistic interaction. Life Sci. 31, 1703–1706.
10. Devane, W. A., Dysarz III F. A., Johnson, M. R., Melvin, L. S., Howlett, A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613.
11. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., Bonner, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564.
12. Gérard, C. M., Mollereau, C., Vassart, G., Parmentier, M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279, 129–134.
13. Munro, S., Thomas, K. L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65.
14. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202.
15. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P. J. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092–1101.
16. Nevalainen, T., Irving, A. J. (2010) GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr. Top. Med. Chem. 10, 799–813.
17. Sharir, H., Abood, M. E. (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126, 301–313.
18. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949.
19. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J., Zvi, V. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90.
20. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97.
21. Prescott, S. M., Majerus, P. W. (1983) Characterization of 1,2- diacylglycerol hydrolysis in human platelets: demonstration of an arachidonoyl-monoacylglycerol intermediate. J. Biol. Chem. 258, 764–769.
22. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., Mechoulam, R. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662–3665.
23. Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., Felder, C. C. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020–1024.
24. Ralevic, V. (2003) Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur. J. Pharmacol. 472, 1–21.
25. Bradshaw, H. B., Walker, J. M. (2005) The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144, 459–465.
26. Pertwee, R. G. (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7, E625–E654.
27. Buczynski, M. W., Parsons, L. H. (2010) Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br. J. Pharmacol. 160, 423–442.
28. Walter, L., Franklin, A., Witting, A., Moller, T., Stella, N. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277, 20869–20876.
29. Walter, L., Stella, N. (2003) Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. Glia 44, 85–90.
30. Matias, I., Pochard, P., Orlando, P., Salzet, M., Pestel, J., Di Marzo, V. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur. J. Biochem. 269, 3771–3778.
31. Maccarrone, M., De Petrocellis, L., Bari, M., Fezza, F., Salvati, S., Di Marzo, V., Finazzi-Agr ò, A. (2001) Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys. 393, 321–328.
32. Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., Di Marzo, V. (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272, 3315–3323.
33. Witting, A., Walter, L., Wacker, J., Möller, T., Stella, N. (2004) P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc. Natl. Acad. Sci. USA 101, 3214–3219.
34. Carrier, E. J., Kearn, C. S., Barkmeier, A. J., Breese, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., Hillard, C. J. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2- arachidonylglycerol, which increases proliferation via a CB2 receptordependent mechanism. Mol. Pharmacol. 65, 999–1007.
35. Rouzer, C. A., Marnett, L. J. (2005) Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. J. Biol. Chem. 280, 26690–26700.
36. Hsu, K. L., Tsuboi, K., Adibekian, A., Pugh, H., Masuda, K., Cravatt, B. F. (2012) DAGLb inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat. Chem. Biol. 8, 999–1007.
37. Di Marzo, V., De Petrocellis, L., Sepe, N., Buono, A. (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316, 977–984.
38. Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., Kunos, G. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258–267.
39. Varga, K., Wagner, J. A., Bridgen, D. T., Kunos, G. (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035–1044.
40. Pestonjamasp, V. K., Burstein, S. H. (1998) Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim. Biophys. Acta 1394, 249–260.
41. Jiang, L. S., Pu, J., Han, Z. H., Hu, L. H., He, B. (2009) Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc. Res. 81, 805–813.
42. Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. (2001) Activation of PAF receptors results in enhanced synthesis of 2- arachidonoylglycerol (2-AG) in immune cells. FASEB J. 15, 2171–2178.
43. Arreaza, G., Devane, W. A., Omeir, R. L., Sajnani, G., Kunz, J., Cravatt, B. F., Deutsch, D. G. (1997) The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci. Lett. 234, 59–62.
44. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., Lichtman, A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371–9376.
45. Natarajan, V., Reddy, P. V., Schmid, P. C., Schmid, H. H. (1982) NAcylation of ethanolamine phospholipids in canine myocardium. Biochim. Biophys. Acta 712, 342–355.
46. Jin, X. H., Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., Ueda, N. (2007) Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J. Biol. Chem. 282, 3614–3623.
47. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691.
48. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., Ueda, N. (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298–5305.
49. Hansen, H. S., Lauritzen, L., Strand, A. M., Moesgaard, B., Frandsen, A. (1995) Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Biochim. Biophys. Acta 1258, 303–308.
50. Leung, D., Saghatelian, A., Simon, G. M., Cravatt, B. F. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720–4726.
51. Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., Chan, A. C., Zhou, Z., Huang, B. X., Kim, H. Y., Kunos, G. (2006) A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA 103, 13345–13350.
52. Sun, Y. X., Tsuboi, K., Okamoto, Y., Tonai, T., Murakami, M., Kudo, I., Ueda, N. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380, 749–756.
53. Simon, G. M., Cravatt, B. F. (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for a/b-hydrolase 4 in this pathway. J. Biol. Chem. 281, 26465–26472.
54. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., Sugiura, T. (1998) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett. 429, 152–156.
55. Bisogno, T., Melck, D., De Petrocellis, L., Di Marzo, V. (1999) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113–2119.
56. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463–468.
57. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., Kano, M. (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65, 320–327.
58. Nakane, S., Oka, S., Arai, S., Waku, K., Ishima, Y., Tokumura, A., Sugiura, T. (2002) 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch. Biochem. Biophys. 402, 51–58.
59. Yates, M. L., Barker, E. L. (2009) Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol. Pharmacol. 76, 11–17.
60. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87.
61. Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., Cravatt, B. F. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281, 36569–36578.
62. McKinney, M. K., Cravatt, B. F. (2005) Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74, 411–432.
63. Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R. C., Cravatt, B. F. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411–420.
64. Clapper, J. R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Sciolino, N. R., Spradley, J. M., Hohmann, A. G., Calignano, A., Mor, M., Tarzia, G., Piomelli, D. (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265–1270.
65. Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., Lichtman, A. H. (2011) Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 99, 718–725.
66. Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76–81.
67. Blankman, J. L., Simon, G. M., Cravatt, B. F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol. Chem. Biol. 14, 1347–1356.
68. Muccioli, G. G., Xu, C., Odah, E., Cudaback, E., Cisneros, J. A., Lambert, D. M., López Rodríguez, M. L., Bajjalieh, S., Stella, N. (2007) Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci. 27, 2883–2889.
69. Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., Bodor, A. L., Muccioli, G. G., Hu, S. S., Woodruff, G., Fung, S., Lafourcade, M., Alexander, J. P., Long, J. Z., Li, W., Xu, C., Möller, T., Mackie, K., Manzoni, O. J., Cravatt, B. F., Stella, N. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 13, 951–957.
70. Marrs, W. R., Horne, E. A., Ortega-Gutierrez, S., Cisneros, J. A., Xu, C., Lin, Y. H., Muccioli, G. G., Lopez-Rodriguez, M. L., Stella, N. (2011) Dual inhibition of a/b-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. J. Biol. Chem. 286, 28723–28728.
71. Xie, S., Borazjani, A., Hatfield, M. J., Edwards, C. C., Potter, P. M., Ross, M. K. (2010) Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. Chem. Res. Toxicol. 23, 1890–1904.
72. Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., Lichtman, A. H., Cravatt, B. F. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5, 37–44.
73. Chanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P., Piesla, M. J., Zhang, M. Y., Bingham, B., Uveges, A., Kowal, D., Garbe, D., Kouranova, E. V., Ring, R. H., Bates, B., Pangalos, M. N., Kennedy, J. D., Whiteside, G. T., Samad, T. A. (2010) Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 78, 996–1003.
74. Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selley, D. E., Sim-Selley, L. J., Liu, Q. S., Lichtman, A. H., Cravatt, B. F. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113–1119.
75. Yu, M., Ives, D., Ramesha, C. S. (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 272, 21181–21186.
76. Burstein, S. H., Rossetti, R. G., Yagen, B., Zurier, R. B. (2000) Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 61, 29–41.
77. Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L. H., Ma, Y. H., Weinander, R., Jakobsson, P. J., Marnett, L. J. (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem. 277, 44877–44885.
78. Koda, N., Tsutsui, Y., Niwa, H., Ito, S., Woodward, D. F., Watanabe, K. (2004) Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. Arch. Biochem. Biophys. 424, 128–136.
79. Yang, W., Ni, J., Woodward, D. F., Tang-Liu, D. D., Ling, K. H. (2005) Enzymatic formation of prostamide F2a from anandamide involves a newly identified intermediate metabolite, prostamide H2. J. Lipid Res. 46, 2745–2751.
80. Woodward, D. F., Krauss, A. H., Chen, J., Liang, Y., Li, C., Protzman, C. E., Bogardus, A., Chen, R., Kedzie, K. M., Krauss, H. A., Gil, D. W., Kharlamb, A., Wheeler, L. A., Babusis, D., Welty, D., Tang- Liu, D. D., Cherukury, M., Andrews, S. W., Burk, R. M., Garst, M. E. (2003) Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305, 772–785.
81. Weber, A., Ni, J., Ling, K. H., Acheampong, A., Tang-Liu, D. D., Burk, R., Cravatt, B. F., Woodward, D. (2004) Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J. Lipid Res. 45, 757–763.
82. Berglund, B. A., Boring, D. L., Howlett, A. C. (1999) Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv. Exp. Med. Biol. 469, 527–533.
83. Ross, R. A., Craib, S. J., Stevenson, L. A., Pertwee, R. G., Henderson, A., Toole, J., Ellington, H. C. (2002) Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J. Pharmacol. Exp. Ther. 301, 900–907.
84. Rockwell, C. E., Kaminski, N. E. (2004) A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 311, 683–690.
85. Matias, I., Chen, J., De Petrocellis, L., Bisogno, T., Ligresti, A., Fezza, F., Krauss, A. H., Shi, L., Protzman, C. E., Li, C., Liang, Y., Nieves, A. L., Kedzie, K. M., Burk, R. M., Di Marzo, V., Woodward, D. F. (2004) Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther. 309, 745–757.
86. Woodward, D. F., Carling, R. W., Cornell, C. L., Fliri, H. G., Martos, J. L., Pettit, S. N., Liang, Y., Wang, J. W. (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol. Ther. 120, 71–80.
87. Kozak, K. R., Rowlinson, S. W., Marnett, L. J. (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 275, 33744–33749.
88. Nirodi, C. S., Crews, B. C., Kozak, K. R., Morrow, J. D., Marnett, L. J. (2004) The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proc. Natl. Acad. Sci. USA 101, 1840–1845.
89. Hampson, A. J., Hill, W. A., Zan-Phillips, M., Makriyannis, A., Leung, E., Eglen, R. M., Bornheim, L. M. (1995) Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim. Biophys. Acta 1259, 173–179.
90. Ueda, N., Yamamoto, K., Yamamoto, S., Tokunaga, T., Shirakawa, E., Shinkai, H., Ogawa, M., Sato, T., Kudo, I., Inoue, K., Takizawa, H., Nagano, T., Hirobe, M., Matasuki, N., Saito, H. (1995) Lipoxygenasecatalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim. Biophys. Acta 1254, 127–134.
91. Moody, J. S., Kozak, K. R., Ji, C., Marnett, L. J. (2001) Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40, 861–866.
92. Kozak, K. R., Gupta, R. A., Moody, J. S., Ji, C., Boeglin, W. E., DuBois, R. N., Brash, A. R., Marnett, L. J. (2002) 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferatoractivated receptor alpha agonist. J. Biol. Chem. 277, 23278–23286.
93. Edgemond, W. S., Hillard, C. J., Falck, J. R., Kearn, C. S., Campbell, W. B. (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol. Pharmacol. 54, 180–188.
94. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., Finazzi-Agro, A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31938–31945.
95. Craib, S. J., Ellington, H. C., Pertwee, R. G., Ross, R. A. (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol. 134, 30–37.
96. Kagaya, M., Lamb, J., Robbins, J., Page, C. P., Spina, D. (2002) Characterization of the anandamide induced depolarization of guineapig isolated vagus nerve. Br. J. Pharmacol. 137, 39–48.
97. Snider, N. T., Kornilov, A. M., Kent, U. M., Hollenberg, P. F. (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J. Pharmacol. Exp. Ther. 321, 590–597.
98. Stark, K., Dostalek, M., Guengerich, F. P. (2008) Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J. 275, 3706–3717.
99. Chen, J. K., Chen, J., Imig, J. D., Wei, S., Hachey, D. L., Guthi, J. S., Falck, J. R., Capdevila, J. H., Harris, R. C. (2008) Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J. Biol. Chem. 283, 24514–24524.
100. Awumey, E. M., Hill, S. K., Diz, D. I., Bukoski, R. D. (2008) Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. Am. J. Physiol. Heart Circ. Physiol. 294, H2363–H2370.
101. Snider, N. T., Nast, J. A., Tesmer, L. A., Hollenberg, P. F. (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol. Pharmacol. 75, 965–972.
102. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54–61.
103. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G., Casellas, P. (1993) Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214, 173–180.
104. Chouinard, F., Lefebvre, J. S., Navarro, P., Bouchard, L., Ferland, C., Lalancette-Hébert, M., Marsolais, D., Laviolette, M., Flamand, N. (2011) The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B4 biosynthesis. J. Immunol. 186, 3188–3196.
105. Chouinard, F., Turcotte, C., Guan, X., Larose, M. C., Poirier, S., Bouchard, L., Provost, V., Flamand, L., Grandvaux, N., Flamand, N. (2013) 2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. J. Leukoc. Biol. 93, 267–276.
106. Oka, S., Ikeda, S., Kishimoto, S., Gokoh, M., Yanagimoto, S., Waku, K., Sugiura, T. (2004) 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J. Leukoc. Biol. 76, 1002–1009.
107. Kurihara, R., Tohyama, Y., Matsusaka, S., Naruse, H., Kinoshita, E., Tsujioka, T., Katsumata, Y., Yamamura, H. (2006) Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J. Biol. Chem. 281, 12908–12918.
108. Graham, E. S., Angel, C. E., Schwarcz, L. E., Dunbar, P. R., Glass, M. (2010) Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int. J. Immunopathol. Pharmacol. 23, 25–34.
109. Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., Graham, E. S. (2008) Specific detection of CB1 receptors: cannabinoid CB1 receptor antibodies are not all created equal! J. Neurosci. Methods 171, 78–86.
110. Bouaboula, M., Bourrié, B., Rinaldi-Carmona, M., Shire, D., Le Fur, G., Casellas, P. (1995) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270, 13973–13980.
111. Small-Howard, A. L., Shimoda, L. M., Adra, C. N., Turner, H. (2005) Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem. J. 388, 465–473.
112. Carayon, P., Marchand, J., Dussossoy, D., Derocq, J. M., Jbilo, O., Bord, A., Bouaboula, M., Galiègue, S., Mondière, P., Pénarier, G., Fur, G. L., Defrance, T., Casellas, P. (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92, 3605–3615.
113. Castaneda, J. T., Harui, A., Kiertscher, S. M., Roth, J. D., Roth, M. D. (2013) Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes. J. Neuroimmune Pharmacol. 8, 323–332.
114. Samson, M. T., Small-Howard, A., Shimoda, L. M., Koblan- Huberson, M., Stokes, A. J., Turner, H. (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol. 170, 4953–4962.
115. Sugawara, K., Zákány, N., Hundt, T., Emelianov, V., Tsuruta, D., Schäfer, C., Kloepper, J. E., Bíró, T., Paus, R. (2013) Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ. J. Allergy Clin. Immunol. 132, 182–193.
116. Sugawara, K., Bíró, T., Tsuruta, D., Tóth, B. I., Kromminga, A., Zákány, N., Zimmer, A., Funk, W., Gibbs, B. F., Zimmer, A., Paus, R. (2012) Endocannabinoids limit excessive mast cell maturation and activation in human skin. J. Allergy Clin. Immunol. 129, 726–738, e8.
117. Han, K. H., Lim, S., Ryu, J., Lee, C. W., Kim, Y., Kang, J. H., Kang, S. S., Ahn, Y. K., Park, C. S., Kim, J. J. (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84, 378–386.
118. Ramirez, S. H., Reichenbach, N. L., Fan, S., Rom, S., Merkel, S. F., Wang, X., Ho, W. Z., Persidsky, Y. (2013) Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J. Leukoc. Biol. 93, 801–810.
119. Klegeris, A., Bissonnette, C. J., McGeer, P. L. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139, 775–786.
120. Montecucco, F., Burger, F., Mach, F., Steffens, S. (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 294, H1145–H1155.
121. Catani, M. V., Gasperi, V., Catanzaro, G., Baldassarri, S., Bertoni, A., Sinigaglia, F., Avigliano, L., Maccarrone, M. (2010) Human platelets express authentic CB₁ and CB₂ receptors. Curr. Neurovasc. Res. 7, 311–318.
122. Signorello, M. G., Giacobbe, E., Passalacqua, M., Leoncini, G. (2013) The 2-arachidonoylglycerol effect on myosin light chain phosphorylation in human platelets. Biochimie 95, 1620–1628.
123. Sánchez López, A. J., Román-Vega, L., Ramil Tojeiro, E., Giuffrida, A., García-Merino, A. (2015) Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-b: a longitudinal study in multiple sclerosis patients. Clin. Exp. Immunol. 179, 119–127.
124. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E. (2001) An endogenous cannabinoid (2- AG) is neuroprotective after brain injury. Nature 413, 527–531.
125. Muthian, S., Rademacher, D. J., Roelke, C. T., Gross, G. J., Hillard, C. J. (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129, 743–750.
126. Kurabayashi, M., Takeyoshi, I., Yoshinari, D., Matsumoto, K., Maruyama, I., Morishita, Y. (2005) 2-Arachidonoylglycerol increases in ischemiareperfusion injury of the rat liver. J. Invest. Surg. 18, 25–31.
127. Bisogno, T., Martire, A., Petrosino, S., Popoli, P., Di Marzo, V. (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem. Int. 52, 307–313.
128. Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., Martino, G., Maccarrone, M. (2007) The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130, 2543–2553.
129. Richardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., Kendall, D. A., Scammell, B. E., Reeve, A. J., Chapman, V. (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 10, R43.
130. Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., Ogawa, H. (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28–36.
131. Kase, Y., Obata, T., Okamoto, Y., Iwai, K., Saito, K., Yokoyama, K., Takinami, M., Tanifuji, Y. (2008) Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial. 12, 374–380.
132. D’Argenio, G., Valenti, M., Scaglione, G., Cosenza, V., Sorrentini, I., Di Marzo, V. (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20, 568–570.
133. Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., Mechoulam, R., Buettner, R., Werner, S., Di Marzo, V., Tüting, T., Zimmer, A. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316, 1494–1497.
134. Hegde, V. L., Hegde, S., Cravatt, B. F., Hofseth, L. J., Nagarkatti, M., Nagarkatti, P. S. (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 74, 20–33.
135. Bátkai, S., Osei-Hyiaman, D., Pan, H., El-Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey-White, J., Jafri, A., Haskó, G., Huffman, J. W., Gao, B., Kunos, G., Pacher, P. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 21, 1788–1800.
136. Caraceni, P., Pertosa, A. M., Giannone, F., Domenicali, M., Grattagliano, I., Principe, A., Mastroleo, C., Perrelli, M. G., Cutrin, J., Trevisani, F., Croci, T., Bernardi, M. (2009) Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 58, 1135–1143.
137. Berdyshev, E., Boichot, E., Corbel, M., Germain, N., Lagente, V. (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci. 63, PL125–PL129.
138. Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., Costa, B. (2007) The inhibition of monoacylglycerol lipase by URB602 showed an antiinflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br. J. Pharmacol. 152, 787–794.
139. Guindon, J., Desroches, J., Beaulieu, P. (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br. J. Pharmacol. 150, 693–701.
140. Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., Lichtman, A. H. (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J. Pharmacol. Exp. Ther. 334, 182–190.
141. Engel, M. A., Kellermann, C. A., Burnat, G., Hahn, E. G., Rau, T., Konturek, P. C. (2010) Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. J. Physiol. Pharmacol. 61, 89–97.
142. Csóka, B., Németh, Z. H., Mukhopadhyay, P., Spolarics, Z., Rajesh, M., Federici, S., Deitch, E. A., Bátkai, S., Pacher, P., Haskó, G. (2009) CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS ONE 4, e6409.
143. Mestre, L., Correa, F., Arévalo-Martín, A., Molina-Holgado, E., Valenti, M., Ortar, G., Di Marzo, V., Guaza, C. (2005) Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92, 1327–1339.
144. Karmaus, P. W., Chen, W., Crawford, R. B., Harkema, J. R., Kaplan, B. L., Kaminski, N. E. (2011) Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J. Leukoc. Biol. 90, 983–995.
145. Sasso, O., Bertorelli, R., Bandiera, T., Scarpelli, R., Colombano, G., Armirotti, A., Moreno-Sanz, G., Reggiani, A., Piomelli, D. (2012) Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol. Res. 65, 553–563.
146. Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., Lichtman, A. H. (2012) The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br. J. Pharmacol. 165, 2485–2496.
147. Schuelert, N., Johnson, M. P., Oskins, J. L., Jassal, K., Chambers, M. G., McDougall, J. J. (2011) Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 152, 975–981.
148. Rettori, E., De Laurentiis, A., Zorrilla Zubilete, M., Rettori, V., Elverdin, J. C. (2012) Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. Neuroimmunomodulation 19, 293–303.
149. Murphy, N., Cowley, T. R., Blau, C. W., Dempsey, C. N., Noonan, J., Gowran, A., Tanveer, R., Olango, W. M., Finn, D. P., Campbell, V. A., Lynch, M. A. (2012) The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J. Neuroinflammation 9, 79.
150. Kerr, D. M., Burke, N. N., Ford, G. K., Connor, T. J., Harhen, B., Egan, L. J., Finn, D. P., Roche, M. (2012) Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 204, 53–63.
151. Lara-Celador, I., Castro-Ortega, L., Alvarez, A., Goñi-de-Cerio, F., Lacalle, J., Hilario, E. (2012) Endocannabinoids reduce cerebral damage after hypoxic-ischemic injury in perinatal rats. Brain Res. 1474, 91–99.
152. Caprioli, A., Coccurello, R., Rapino, C., Di Serio, S., Di Tommaso, M., Vertechy, M., Vacca, V., Battista, N., Pavone, F., Maccarrone, M., Borsini, F. (2012) The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J. Pharmacol. Exp. Ther. 342, 188–195.
153. Wang, Z. Y., Wang, P., Hillard, C. J., Bjorling, D. E. (2015) Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase. J. Mol. Neurosci. 55, 968–976.
154. Krustev, E., Reid, A., McDougall, J. J. (2014) Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints. Arthritis Res. Ther. 16, 437.
155. Tchantchou, F., Tucker, L. B., Fu, A. H., Bluett, R. J., McCabe, J. T., Patel, S., Zhang, Y. (2014) The fatty acid amide hydrolase inhibitor PF- 3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology 85, 427–439.
156. Jackson, A. R., Nagarkatti, P., Nagarkatti, M. (2014) Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS ONE 9, e93954.
157. Sałaga, M., Mokrowiecka, A., Zakrzewski, P. K., Cygankiewicz, A., Leishman, E., Sobczak, M., Zatorski, H., Małecka-Panas, E., Kordek, R., Storr, M., Krajewska, W. M., Bradshaw, H. B., Fichna, J. (2014) Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J. Crohn’s Colitis 8, 998–1009.
158. Hernangómez, M., Mestre, L., Correa, F. G., Loría, F., Mecha, M., Iñigo, P. M., Docagne, F., Williams, R. O., Borrell, J., Guaza, C. (2012) CD200- CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 60, 1437–1450.
159. Lourbopoulos, A., Grigoriadis, N., Lagoudaki, R., Touloumi, O., Polyzoidou, E., Mavromatis, I., Tascos, N., Breuer, A., Ovadia, H., Karussis, D., Shohami, E., Mechoulam, R., Simeonidou, C. (2011) Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 1390, 126–141.
160. Tchantchou, F., Zhang, Y. (2013) Selective inhibition of alpha/betahydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J. Neurotrauma 30, 565–579.
161. Kerr, D. M., Harhen, B., Okine, B. N., Egan, L. J., Finn, D. P., Roche, M. (2013) The monoacylglycerol lipase inhibitor JZL184 attenuates LPSinduced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br. J. Pharmacol. 169, 808–819.
162. Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., Samad, T. A. (2012) A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell Reports 1, 617–623.
163. Cao, Z., Mulvihill, M. M., Mukhopadhyay, P., Xu, H., Erdélyi, K., Hao, E., Holovac, E., Haskó, G., Cravatt, B. F., Nomura, D. K., Pacher, P. (2013) Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 144, 808–817, e15.
164. Ignatowska-Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O’Neal, S. T., Walentiny, D. M., Wiley, J. L., Cravatt, B. F., Lichtman, A. H. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects. Br. J. Pharmacol. 171, 1392–1407.
165. Crowe, M. S., Leishman, E., Banks, M. L., Gujjar, R., Mahadevan, A., Bradshaw, H. B., Kinsey, S. G. (2014) Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice. Br. J. Pharmacol. doi:10.1111/bph.13012 [Epub ahead of print].
166. Costola-de-Souza, C., Ribeiro, A., Ferraz-de-Paula, V., Calefi, A. S., Aloia, T. P., Gimenes-Júnior, J. A., de Almeida, V. I., Pinheiro, M. L., Palermo-Neto, J. (2013) Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PLoS ONE 8, e77706.
167. Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J., Guaza, C. (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 40, 258–266.
168. Xu, H., Cheng, C. L., Chen, M., Manivannan, A., Cabay, L., Pertwee, R. G., Coutts, A., Forrester, J. V. (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol. 82, 532–541.
169. Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., Ledent, C., Cheng, X., Carrier, E. J., Mann, M. K., Giovannoni, G., Pertwee, R. G., Yamamura, T., Buckley, N. E., Hillard, C. J., Lutz, B., Baker, D., Dittel, B. N. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492–497.
170. Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Karsak, M., Zimmer, A., Frossard, J. L., Mach, F. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Correction (2005). Nature. 435, 528]. Nature 434, 782–786.
171. Zhao, Y., Liu, Y., Zhang, W., Xue, J., Wu, Y. Z., Xu, W., Liang, X., Chen, T., Kishimoto, C., Yuan, Z. (2010) WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur. J. Pharmacol. 649, 285–292.
172. Jan, T. R., Farraj, A. K., Harkema, J. R., Kaminski, N. E. (2003) Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol. Appl. Pharmacol. 188, 24–35.
173. Li, X., Kaminski, N. E., Fischer, L. J. (2001) Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int. Immunopharmacol. 1, 699–712.
174. Di Filippo, C., Rossi, F., Rossi, S., D’Amico, M. (2004) Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol. 75, 453–459.
175. Smith, S. R., Denhardt, G., Terminelli, C. (2001) The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur. J. Pharmacol. 432, 107–119.
176. Klein, T. W., Newton, C. A., Nakachi, N., Friedman, H. (2000) D 9- tetrahydrocannabinol treatment suppresses immunity and early IFN-g, IL-12, and IL-12 receptor b 2 responses to Legionella pneumophila infection. J. Immunol. 164, 6461–6466.
177. Mishkin, E. M., Cabral, G. A. (1985) delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J. Gen. Virol. 66, 2539–2549.
178. Morahan, P. S., Klykken, P. C., Smith, S. H., Harris, L. S., Munson, A. E. (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect. Immun. 23, 670–674.
179. McKallip, R. J., Nagarkatti, M., Nagarkatti, P. S. (2005) D-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174, 3281–3289.
180. O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A., Randall, M. D. (2005) Novel time-dependent vascular actions of D9- tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor g. Biochem. Biophys. Res. Commun. 337, 824–831.
181. Sun, Y., Alexander, S. P., Kendall, D. A., Bennett, A. J. (2006) Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 34, 1095–1097.
182. O’Sullivan, S. E., (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol., 152, 576–582.
183. Newton, C. A., Chou, P. J., Perkins, I., Klein, T. W. (2009) CB1 and CB2 cannabinoid receptors mediate different aspects of delta-9- tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J. Neuroimmune Pharmacol. 4, 92–102.
184. Buchweitz, J. P., Karmaus, P. W., Williams, K. J., Harkema, J. R., Kaminski, N. E. (2008) Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/ PR/8/34 in the absence and presence of D9-tetrahydrocannabinol. J. Leukoc. Biol. 83, 785–796.
185. Braun, A., Engel, T., Aguilar-Pimentel, J. A., Zimmer, A., Jakob, T., Behrendt, H., Mempel, M. (2011) Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors. Immunobiology 216, 466–476.
186. Giannini, L., Nistri, S., Mastroianni, R., Cinci, L., Vannacci, A., Mariottini, C., Passani, M. B., Mannaioni, P. F., Bani, D., Masini, E. (2008) Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. J. Cell. Mol. Med. 12(6A), 2381–2394.
187. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., de Ceballos, M. L. (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904–1913.
188. Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Kuhn, M. N., Zvonok, A. M., Thakur, G. A., Makriyannis, A., Milligan, E. D. (2012) Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal antiinflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav. 2, 155–177.
189. Zarruk, J. G., Fernández-López, D., García-Yébenes, I., García-Gutiérrez, M. S., Vivancos, J., Nombela, F., Torres, M., Burguete, M. C., Manzanares, J., Lizasoain, I., Moro, M. A. (2012) Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 43, 211–219.
190. Amenta, P. S., Jallo, J. I., Tuma, R. F., Elliott, M. B. (2012) A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J. Neurosci. Res. 90, 2293–2305.
191. Ossola, C. A., Surkin, P. N., Pugnaloni, A., Mohn, C. E., Elverdin, J. C., Fernandez-Solari, J. (2012) Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflamm. Res. 61, 941–948.
192. Sardinha, J., Kelly, M. E., Zhou, J., Lehmann, C. (2014) Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm. 2014, 978678.
193. Tambaro, S., Casu, M. A., Mastinu, A., Lazzari, P. (2014) Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Eur. J. Pharmacol. 729, 67–74.
194. Zoppi, S., Madrigal, J. L., Caso, J. R., García-Gutiérrez, M. S., Manzanares, J., Leza, J. C., García-Bueno, B. (2014) Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice. Br. J. Pharmacol. 171, 2814–2826.
195. Carrier, E. J., Auchampach, J. A., Hillard, C. J. (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. USA 103, 7895–7900.
196. Haskó, G., Pacher, P. (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol. 83, 447–455.
197. Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., Thiel, M. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxiainducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657–682.
198. Ohta, A., Sitkovsky, M. (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920.
199. Coopman, K., Smith, L. D., Wright, K. L., Ward, S. G. (2007) Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int. Immunopharmacol. 7, 360–371.
200. McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G., Ross, R. A. (2008) Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol. Pharmacol. 73, 441–450.
201. Ortega-Gutiérrez, S., Molina-Holgado, E., Guaza, C. (2005) Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 52, 163–168.
202. Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., Ullrich, O. (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67–79.
203. Rockwell, C. E., Raman, P., Kaplan, B. L. F., Kaminski, N. E. A. (2008) A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem. Pharmacol. 76, 353–361.
204. Cencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., Maccarrone, M. (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5, e8688.
205. Berdyshev, E. V., Boichot, E., Germain, N., Allain, N., Anger, J. P., Lagente, V. (1997) Influence of fatty acid ethanolamides and delta9- tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol. 330, 231–240.
206. Correa, F., Hernangómez, M., Mestre, L., Loría, F., Spagnolo, A., Docagne, F., Di Marzo, V., Guaza, C. (2010) Anandamide enhances IL- 10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 58, 135–147.
207. Joseph, J., Niggemann, B., Zaenker, K. S., Entschladen, F. (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother. 53, 723–728.
208. Ghosh, S., Preet, A., Groopman, J. E., Ganju, R. K. (2006) Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol. 43, 2169–2179.
209. Murikinati, S., Jüttler, E., Keinert, T., Ridder, D. A., Muhammad, S., Waibler, Z., Ledent, C., Zimmer, A., Kalinke, U., Schwaninger, M. (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 24, 788–798.
210. Sacerdote, P., Massi, P., Panerai, A. E., Parolaro, D. (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 109, 155–163.
211. Raborn, E. S., Marciano-Cabral, F., Buckley, N. E., Martin, B. R., Cabral, G. A. (2008) The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J. Neuroimmune Pharmacol. 3, 117–129.
212. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., Vogel, Z. (2010) Cannabinoids D(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-b/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285, 1616–1626.
213. Sheng, W. S., Hu, S., Min, X., Cabral, G. A., Lokensgard, J. R., Peterson, P. K. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1b-stimulated human astrocytes. Glia 49, 211–219.
214. Hao, M. X., Jiang, L. S., Fang, N. Y., Pu, J., Hu, L. H., Shen, L. H., Song, W., He, B. (2010) The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J. Lipid Res. 51, 2181–2190.
215. Yuan, M., Kiertscher, S. M., Cheng, Q., Zoumalan, R., Tashkin, D. P., Roth, M. D. (2002) D 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133, 124–131.
216. Chiurchiù, V., Cencioni, M. T., Bisicchia, E., De Bardi, M., Gasperini, C., Borsellino, G., Centonze, D., Battistini, L., Maccarrone, M. (2013) Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann. Neurol. 73, 626–636.
217. Gallily, R., Breuer, A., Mechoulam, R. (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-a production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5–R7.
218. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P., Marciano-Cabral, F. (1995) Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci. 56, 2065–2072.
219. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., Leon, A. (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161–168.
220. Correa, F., Hernangómez-Herrero, M., Mestre, L., Loría, F., Docagne, F., Guaza, C. (2011) The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav. Immun. 25, 736–749.
221. Krishnan, G., Chatterjee, N. (2012) Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia 60, 1629–1645.
222. Krishnan, G., Chatterjee, N. (2014) Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. Mol. Cell. Neurosci. 59, 10–23.
223. Eisenstein, T. K., Meissler, J. J., Wilson, Q., Gaughan, J. P., Adler, M. W. (2007) Anandamide and D9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J. Neuroimmunol. 189, 17–22.
224. Schwarz, H., Blanco, F. J., Lotz, M. (1994) Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55, 107–115.
225. Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P., Kaminski, N. E. (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101–111.
226. Echigo, R., Sugimoto, N., Yachie, A., Ohno-Shosaku, T. (2012) Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-kB and cell growth in U87MG human malignant glioma cells. Oncol. Rep. 28, 1176–1180.
227. De Angelis, V., Koekman, A. C., Weeterings, C., Roest, M., de Groot, P. G., Herczenik, E., Maas, C. (2014) Endocannabinoids control platelet activation and limit aggregate formation under flow. PLoS ONE 9, e108282.
228. Do, Y., McKallip, R. J., Nagarkatti, M., Nagarkatti, P. S. (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NFkappaB- dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 173, 2373–2382.
229. Ross, R. A., Brockie, H. C., Pertwee, R. G. (2000) Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol. 401, 121–130.
230. Friedman, M., Cepero, M. L., Klein, T., Friedman, H. (1986) Suppressive effect of delta 9-tetrahydrocannabinol in vitro on phagocytosis by murine macrophages. Proc. Soc. Exp. Biol. Med. 182, 225–228.
231. Correa, F., Mestre, L., Docagne, F., Guaza, C. (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 145, 441–448.
232. Chang, Y. H., Lee, S. T., Lin, W. W. (2001) Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81, 715–723.
233. McCoy, K. L., Matveyeva, M., Carlisle, S. J., Cabral, G. A. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 289, 1620–1625.
234. Giudice, E. D., Rinaldi, L., Passarotto, M., Facchinetti, F., D’Arrigo, A., Guiotto, A., Carbonare, M. D., Battistin, L., Leon, A. (2007) Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL- 2H3 mast cells. J. Leukoc. Biol. 81, 1512–1522.
235. More, S. V., Park, J. Y., Kim, B. W., Kumar, H., Lim, H. W., Kang, S. M., Koppula, S., Yoon, S. H., Choi, D. K. (2013) Anti-neuroinflammatory activity of a novel cannabinoid derivative by inhibiting the NF-kB signaling pathway in lipopolysaccharide-induced BV-2 microglial cells. J. Pharmacol. Sci. 121, 119–130.
236. Montecucco, F., Lenglet, S., Braunersreuther, V., Burger, F., Pelli, G., Bertolotto, M., Mach, F., Steffens, S. (2009) CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/ reperfusion. J. Mol. Cell. Cardiol. 46, 612–620.
237. Lombard, C., Nagarkatti, M., Nagarkatti, P. (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. 122, 259–270.
238. Maestroni, G. J. (2004) The endogenous cannabinoid 2- arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J. 18, 1914–1916.
239. Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Sakai, M., Costa-Pinto, F. A., Palermo-Neto, J. (2010) Anandamide prior to sensitization increases cell-mediated immunity in mice. Int. Immunopharmacol. 10, 431–439.
240. Mukhopadhyay, P., Pan, H., Rajesh, M., Bátkai, S., Patel, V., Harvey- White, J., Mukhopadhyay, B., Haskó, G., Gao, B., Mackie, K., Pacher, P. (2010) CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 160, 657–668.
241. Mukhopadhyay, P., Rajesh, M., Bátkai, S., Patel, V., Kashiwaya, Y., Liaudet, L., Evgenov, O. V., Mackie, K., Haskó, G., Pacher, P. (2010) CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc. Res. 85, 773–784.
242. Oka, S., Wakui, J., Ikeda, S., Yanagimoto, S., Kishimoto, S., Gokoh, M., Nasui, M., Sugiura, T. (2006) Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J. Immunol. 177, 8796–8805.
243. Oka, S., Yanagimoto, S., Ikeda, S., Gokoh, M., Kishimoto, S., Waku, K., Ishima, Y., Sugiura, T. (2005) Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetateinduced acute inflammation in mouse ear. J. Biol. Chem. 280, 18488–18497.
244. Altinsoy, A., Dileköz, E., Kul, O., Ilhan, S. O., Tunccan, O. G., Seven, I., Bagriacik, E. U., Sarioglu, Y., Or, M., Ercan, Z. S. (2011) A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. J. Ocul. Pharmacol. Ther. 27, 545–552.
245. Lenglet, S., Thomas, A., Soehnlein, O., Montecucco, F., Burger, F., Pelli, G., Galan, K., Cravatt, B., Staub, C., Steffens, S. (2013) Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Arterioscler. Thromb. Vasc. Biol. 33, 215–223.
246. Rayman, N., Lam, K. H., Laman, J. D., Simons, P. J., Löwenberg, B., Sonneveld, P., Delwel, R. (2004) Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J. Immunol. 172, 2111–2117.
247. Jordà, M. A., Verbakel, S. E., Valk, P. J., Vankan-Berkhoudt, Y. V., Maccarrone, M., Finazzi-Agr ò, A., Löwenberg, B., Delwel, R. (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786–2793.
248. Tanikawa, T., Kurohane, K., Imai, Y. (2007) Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice. Microbiol. Immunol. 51, 1013–1019.
249. Kishimoto, S., Oka, S., Gokoh, M., Sugiura, T. (2006) Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. Int. Arch. Allergy Immunol. 140(Suppl 1), 3–7.
250. Larose, M. C., Turcotte, C., Chouinard, F., Ferland, C., Martin, C., Provost, V., Laviolette, M., Flamand, N. (2014) Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. J. Allergy Clin. Immunol. 133, 1480-1482.
251. Gasperi, V., Evangelista, D., Chiurchiù, V., Florenzano, F., Savini, I., Oddi, S., Avigliano, L., Catani, M. V., Maccarrone, M. (2014) 2- Arachidonoylglycerol modulates human endothelial cell/leukocyte interactions by controlling selectin expression through CB1 and CB2 receptors. Int. J. Biochem. Cell Biol. 51, 79–88.
252. Freeman-Anderson, N. E., Pickle, T. G., Netherland, C. D., Bales, A., Buckley, N. E., Thewke, D. P. (2008) Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/ oxysterol-induced apoptosis. J. Lipid Res. 49, 2338–2346.
253. Shiratsuchi, A., Watanabe, I., Yoshida, H., Nakanishi, Y. (2008) Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. Immunol. Cell Biol. 86, 179–184.
254. Kishimoto, S., Gokoh, M., Oka, S., Muramatsu, M., Kajiwara, T., Waku, K., Sugiura, T. (2003) 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem. 278, 24469–24475.
255. Kishimoto, S., Kobayashi, Y., Oka, S., Gokoh, M., Waku, K., Sugiura, T. (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem. 135, 517–524.
256. Gokoh, M., Kishimoto, S., Oka, S., Mori, M., Waku, K., Ishima, Y., Sugiura, T. (2005) 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem. J. 386, 583–589.
257. Lau, A. H., Chow, S. S. (2003) Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur. J. Pharmacol. 464, 229–235.
258. Yoo, J. M., Sok, D. E., Kim, M. R. (2013) Effect of endocannabinoids on IgE-mediated allergic response in RBL-2H3 cells. Int. Immunopharmacol. 17, 123–131.
259. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23, 1398–1405.
260. Stefano, G. B., Bilfinger, T. V., Rialas, C. M., Deutsch, D. G. (2000) 2- arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol. Res. 42, 317–322.
261. Kishimoto, S., Muramatsu, M., Gokoh, M., Oka, S., Waku, K., Sugiura, T. (2005) Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. 137, 217–223.
262. Brantl, S. A., Khandoga, A. L., Siess, W. (2014) Mechanism of platelet activation induced by endocannabinoids in blood and plasma. Platelets. 25, 151–161.
263. Signorello, M. G., Leoncini, G. (2014) Effect of 2-arachidonoylglycerol on myosin light chain phosphorylation and platelet activation: the role of phosphatidylinositol 3 kinase/AKT pathway. Biochimie 105, 182–191.
264. Gokoh, M., Kishimoto, S., Oka, S., Metani, Y., Sugiura, T. (2005) 2- Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophagelike cells and human peripheral blood monocytes. FEBS Lett. 579, 6473–6478.
265. Gokoh, M., Kishimoto, S., Oka, S., Sugiura, T. (2007) 2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. Biol. Pharm. Bull. 30, 1199–1205.
266. Baldassarri, S., Bertoni, A., Bagarotti, A., Sarasso, C., Zanfa, M., Catani, M. V., Avigliano, L., Maccarrone, M., Torti, M., Sinigaglia, F. (2008) The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. J. Thromb. Haemost. 6, 1772–1779.
267. Feng, L., Sun, W., Xia, Y., Tang, W. W., Chanmugam, P., Soyoola, E., Wilson, C. B., Hwang, D. (1993) Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch. Biochem. Biophys. 307, 361–368.
268. Hu, S. S., Bradshaw, H. B., Chen, J. S., Tan, B., Walker, J. M. (2008) Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2- arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br. J. Pharmacol. 153, 1538–1549.
269. Patsos, H. A., Hicks, D. J., Dobson, R. R., Greenhough, A., Woodman, N., Lane, J. D., Williams, A. C., Paraskeva, C. (2005) The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54, 1741–1750.
270. Van Dross, R. T. (2009) Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol. Carcinog. 48, 724–732.
271. Sang, N., Zhang, J., Chen, C. (2007) COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J. Neurochem. 102, 1966–1977.
272. Herradón, E., Martín, M. I., López-Miranda, V. (2007) Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br. J. Pharmacol. 152, 699–708.
273. Ghosh, M., Wang, H., Ai, Y., Romeo, E., Luyendyk, J. P., Peters, J. M., Mackman, N., Dey, S. K., Hla, T. (2007) COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204, 2053–2061.
274. Wahn, H., Wolf, J., Kram, F., Frantz, S., Wagner, J. A. (2005) The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am. J. Physiol. Heart Circ. Physiol. 289, H2491–H2496.
275. Brown, K. L., Davidson, J., Rotondo, D. (2013) Characterisation of the prostaglandin E2-ethanolamide suppression of tumour necrosis factor-a production in human monocytic cells. Biochim. Biophys. Acta 1831, 1098–1107.
276. Correa, F., Docagne, F., Clemente, D., Mestre, L., Becker, C., Guaza, C. (2008) Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem. J. 409, 761–770.
277. Keown, O. P., Winterburn, T. J., Wainwright, C. L., Macrury, S. M., Neilson, I., Barrett, F., Leslie, S. J., Megson, I. L. (2010) 2-arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors. Br. J. Clin. Pharmacol. 70, 180–188.
278. Gatta, L., Piscitelli, F., Giordano, C., Boccella, S., Lichtman, A., Maione, S., Di Marzo, V. (2012) Discovery of prostamide F2a and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS ONE 7, e31111.
279. Nicotra, L. L., Vu, M., Harvey, B. S., Smid, S. D. (2013) Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins Other Lipid Mediat. 100-101C, 22-29.
280. Ritter, J. K., Li, C., Xia, M., Poklis, J. L., Lichtman, A. H., Abdullah, R. A., Dewey, W. L., Li, P. L. (2012) Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. J. Pharmacol. Exp. Ther. 342, 770–779.
281. Alhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M., Muccioli, G. G. (2013) Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc. Natl. Acad. Sci. USA 110, 17558–17563.
282. Raman, P., Kaplan, B. L., Kaminski, N. E. (2012) 15-Deoxy- D¹²,¹⁴-prostaglandin J₂-glycerol, a putative metabolite of 2-arachidonyl glycerol and a peroxisome proliferator-activated receptor g ligand, modulates nuclear factor of activated T cells. J. Pharmacol. Exp. Ther. 342, 816–826.
283. Kozak, K. R., Crews, B. C., Ray, J. L., Tai, H. H., Morrow, J. D., Marnett, L. J. (2001) Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J. Biol. Chem. 276, 36993–36998.
284. Savinainen, J. R., Kansanen, E., Pantsar, T., Navia-Paldanius, D., Parkkari, T., Lehtonen, M., Laitinen, T., Nevalainen, T., Poso, A., Levonen, A. L., Laitinen, J. T. (2014) Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL). Mol. Pharmacol. 86, 522–535.
285. Wang, R., Borazjani, A., Matthews, A. T., Mangum, L. C., Edelmann, M. J., Ross, M. K. (2013) Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme. Biochemistry 52, 7559–7574.
286. Manna, J. D., Wepy, J. A., Hsu, K. L., Chang, J. W., Cravatt, B. F., Marnett, L. J. (2014) Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. J. Biol. Chem. 289, 33741–33753.
287. Kroschwald, P., Kroschwald, A., Kühn, H., Ludwig, P., Thiele, B. J., Höhne, M., Schewe, T., Rapoport, S. M. (1989) Occurrence of the erythroid cell specific arachidonate 15-lipoxygenase in human reticulocytes. Biochem. Biophys. Res. Commun. 160, 954–960.
288. Nadel, J. A., Conrad, D. J., Ueki, I. F., Schuster, A., Sigal, E. (1991) Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J. Clin. Invest. 87, 1139–1145.
289. Kühn, H., O’Donnell, V. B. (2006) Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res. 45, 334–356.
290. Amadio, D., Fezza, F., Catanzaro, G., Incani, O., van Zadelhoff, G., Finazzi Agrò, A., Maccarrone, M. (2010) Methylation and acetylation of 15-hydroxyanandamide modulate its interaction with the endocannabinoid system. Biochimie 92, 378–387.
291. Veldhuis, W. B., van der Stelt, M., Wadman, M. W., van Zadelhoff, G., Maccarrone, M., Fezza, F., Veldink, G. A., Vliegenthart, J. F., Bär, P. R., Nicolay, K., Di Marzo, V. (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23, 4127–4133.
292. Endsley, M. P., Aggarwal, N., Isbell, M. A., Wheelock, C. E., Hammock, B. D., Falck, J. R., Campbell, W. B., Nithipatikom, K. (2007) Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int. J. Cancer 121, 984–991.
293. Kojima, S., Sugiura, T., Waku, K., Kamikawa, Y. (2002) Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur. J. Pharmacol. 444, 203–207.
294. Maccarrone, M., Salvati, S., Bari, M., Finazzi-Agró, A. (2000) Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem. Biophys. Res. Commun. 278, 576–583.
295. Starowicz, K., Makuch, W., Korostynski, M., Malek, N., Slezak, M., Zychowska, M., Petrosino, S., De Petrocellis, L., Cristino, L., Przewlocka, B., Di Marzo, V. (2013) Full inhibition of spinal FAAH leads to TRPV1- mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS ONE 8, e60040.
296. Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., Nilius, B. (2003) Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424, 434–438.
297. Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., Cravatt, B. F. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809–813.
298. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., Willoughby, D. A. (1999) Inducible cyclooxygenase may have antiinflammatory properties. Nat. Med. 5, 698–701.